<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113500</url>
  </required_header>
  <id_info>
    <org_study_id>17058</org_study_id>
    <secondary_id>NCI-2017-00573</secondary_id>
    <secondary_id>17058</secondary_id>
    <nct_id>NCT03113500</nct_id>
  </id_info>
  <brief_title>Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma</brief_title>
  <official_title>A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well brentuximab vedotin and combination
      chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma.
      Monoclonal antibodies, such as brentuximab vedotin may interfere with the ability of cancer
      cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin,
      etoposide, and prednisone work in different ways to stop the growth of cancer cells, either
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.
      Giving brentuximab vedotin and combination chemotherapy may work better in treating patients
      with CD30-positive peripheral T-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the safety and tolerability of cyclophosphamide, doxorubicin, etoposide,
      prednisone, and brentuximab vedotin (CHEP-BV), as induction therapy in patients with
      CD30-positive peripheral T-cell lymphoma (PTCL). (Safety lead-in) II. Assess the
      anti-lymphoma activity of CHEP-BV as induction treatment in patients with CD30-positive PTCL.
      (Phase 2)

      SECONDARY OBJECTIVES:

      I. Describe outcomes of CD30-positive PTCL patients who go on to receive BV consolidation
      therapy post CHEP-BV induction with/without autologous hematopoietic cell
      transplantation/radiation.

      TERTIARY OBJECTIVES:

      I. Explore the rate of minimal residual disease (MRD) negativity (as assessed by
      next-generation sequencing) and MRD kinetics after CHEP-BV and BV consolidation therapy in
      CD30-positive PTCL.

      II. Explore the possible association between outcome after study treatment and CD30
      expression, gene expression profiles (GEP), and genetic mutations as measured in PTCL tumor
      samples.

      OUTLINE:

      INDUCTION: Patients receive cyclophosphamide intravenously (IV) and doxorubicin IV on day 1,
      etoposide IV on days 1-3, and prednisone orally (PO) on days 1-5. Patients also receive
      brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6
      courses in the absence of disease progression or unacceptable toxicity.

      CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy or after
      completing induction course 6, patients with objective response (compete response or partial
      response) receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21
      days for up to 10 courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days, 6 months and 12
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR) rate after CHEP-BV induction therapy</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated by the proportion of evaluable patients achieving CR after CHEP-BV induction therapy, along with the 95% exact binomial confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate after BV consolidation therapy</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated by the proportion of evaluable patients achieving CR after BV consolidation therapy, along with the 95% exact binomial confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events after CHEP-BV induction therapy</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be summarized by type (organ affected or laboratory determination such as absolute neutrophil count), severity (by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0 and nadir or maximum values for lab measures), date of onset, duration, reversibility, and attribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of BV consolidation after CHEP-BV induction therapy and ASCT/radiation</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be summarized by type (organ affected or laboratory determination such as absolute neutrophil count), severity (by NCI CTCAE version 4.0 and nadir or maximum values for lab measures), date of onset, duration, reversibility, and attribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of BV consolidation after CHEP-BV induction therapy without ASCT/radiation</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be summarized by type (organ affected or laboratory determination such as absolute neutrophil count), severity (by NCI CTCAE version 4.0 and nadir or maximum values for lab measures), date of onset, duration, reversibility, and attribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate after induction therapy</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated by the proportion of evaluable patients achieving overall response rate after induction therapy. Will be estimated along with the 95% exact binomial confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>The time from enrollment to death from any cause assessed up to 1 year</time_frame>
    <description>Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>The time from enrollment to the first observation of disease relapse/progression or death from any cause, whichever occurs first assessed up to 1 year</time_frame>
    <description>Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Adult T-Cell Leukemia/Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma, ALK-Negative</condition>
  <condition>Anaplastic Large Cell Lymphoma, ALK-Positive</condition>
  <condition>Angioimmunoblastic T-Cell Lymphoma</condition>
  <condition>CD30-Positive Neoplastic Cells Present</condition>
  <condition>Enteropathy-Associated T-Cell Lymphoma</condition>
  <condition>Hepatosplenic T-Cell Lymphoma</condition>
  <condition>Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Peripheral T-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>Stage III Anaplastic Large Cell Lymphoma</condition>
  <condition>Stage IV Anaplastic Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (CHEP-BV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive cyclophosphamide IV, doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy or after completing induction course 6, patients with objective response (compete response or partial response) receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CHEP-BV)</arm_group_label>
    <other_name>ADC SGN-35</other_name>
    <other_name>Adcetris</other_name>
    <other_name>Anti-CD30 Antibody-Drug Conjugate SGN-35</other_name>
    <other_name>Anti-CD30 Monoclonal Antibody-MMAE SGN-35</other_name>
    <other_name>Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35</other_name>
    <other_name>cAC10-vcMMAE</other_name>
    <other_name>SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CHEP-BV)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CHEP-BV)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxydaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CHEP-BV)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (CHEP-BV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (CHEP-BV)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented informed consent of participant and/or legally authorized representative

          -  Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be
             retrieved and submitted post-enrollment

             * If unavailable, exceptions may be granted with study principal investigator (PI)
             approval.

          -  Eastern Cooperative Oncology Group (ECOG) status =&lt; 2

          -  Histologically confirmed mature peripheral T-cell or natural killer (NK)-cell lymphoma
             per World Health Organization (WHO) classification, including:

               -  Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
                  with international protein index (IPI) of 2 or higher (must have stage III-IV
                  disease)

               -  ALK-negative ALCL

               -  PTCL-not otherwise specified (NOS)

               -  Angioimmunoblastic T-cell lymphoma (AITL)

               -  Adult T-cell lymphoma/leukemia (ATLL)

               -  Enteropathy-associated T-cell lymphoma (EATL)

               -  Hepatosplenic T-cell lymphoma

          -  &gt;= 1% of CD30-positivity by immunohistochemistry confirmed by hematopathology review
             at the participating institution

          -  Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission
             tomography (PET)-CT scan

          -  Absolute neutrophil count (ANC) &gt;= 1,000/mm^3

             * Exception: unless documented bone marrow involvement by lymphoma

          -  Platelets &gt;= 50,000/mm^3

             * Exception: unless documented bone marrow involvement by lymphoma

          -  Total serum bilirubin =&lt; 1.5 x upper limit of normal (ULN) OR if hepatic involvement
             by lymphoma: =&lt; 3 x ULN for Gilbert's disease or documented hepatic involvement by
             lymphoma

          -  Aspartate aminotransferase (AST) =&lt; 2 x ULN OR if hepatic involvement by lymphoma: AST
             =&lt; 5 x ULN

          -  Alanine aminotransferase (ALT) =&lt; 2 x ULN OR if hepatic involvement by lymphoma: ALT
             =&lt; 5 x ULN

          -  Creatinine clearance of &gt;= 60 mL/min per the Cockcroft-Gault formula

          -  Left ventricular ejection fraction (LVEF) &gt;= 45%

          -  Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required

          -  Agreement by WOCBP and males of childbearing potential to use an effective method of
             birth control or abstain from heterosexual activity for the course of the study
             through at least 6 months after the last dose of protocol therapy; childbearing
             potential defined as not being surgically sterilized (men and women) or have not been
             free from menses for &gt; 1 year (women only)

        Exclusion Criteria:

          -  Prior Therapies-Brentuximab vedotin

          -  Prior treatment of PTCL with systemic anti-lymphoma therapies, investigational agents,
             radiation

             *Exception: May have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP, EPOCH);
             these participants must initiate Day 1 Cycle 1 of CHEP-BV no less than 19 days from
             prior CHOP-like therapy

          -  History of another primary invasive cancer, hematologic malignancy, or myelodysplastic
             syndrome that has not been in remission for at least 3 years;

             * Exceptions: non-melanoma skin cancer and in situ cervical cancer

          -  Symptomatic cardiac disease (including symptomatic ventricular dysfunction,
             symptomatic coronary artery disease, and symptomatic arrhythmias), cerebrovascular
             event/stroke or myocardial infarction within the past 6 months

          -  Central nervous system involvement by lymphoma, including leptomeningeal involvement

          -  History of progressive multifocal leukoencephalopathy (PML)

          -  Active &gt;= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1
             of protocol therapy

          -  Any known human immunodeficiency virus (HIV) infection, hepatitis B surface
             antigen-positive status, or known or suspected active hepatitis C infection

          -  Baseline peripheral neuropathy &gt;= grade 2 or patients with the demyelinating form of
             Charcot-Marie-Tooth syndrome

          -  Known hypersensitivity to any study related agent excipient(s)

          -  Females only: pregnant or breastfeeding

          -  Any other condition that would, in the investigator's judgement, contraindicate the
             patient's participation in the clinical study due to safety concerns with clinical
             study procedures

          -  Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Herrera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex F. Herrera, MD</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>62405</phone_ext>
      <email>aherrera@coh.org</email>
    </contact>
    <investigator>
      <last_name>Alex F. Herrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tatyana Feldman, MD</last_name>
      <phone>551-996-4469</phone>
      <email>Tatyana.Feldman@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle A. Fanale, MD</last_name>
      <phone>713-792-2860</phone>
      <email>mfanale@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michelle A. Fanale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerry Savage, MD MSc</last_name>
      <phone>604 877-6000</phone>
      <email>ksavage@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Kerry Savage, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

